Clinical trial
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic…
NCT00197145 · ViiV Healthcare, Industry · Terminated
Key facts
| NCT number | NCT00197145 |
|---|---|
| Title | Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects |
| Official title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks. |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I |
| Intervention type | Drug |
| Interventions | GW873140 |
| Enrollment | 24 |
| Start date | Jul 21, 2005 |
| Primary completion | Sep 11, 2007 |
| Completion | Sep 11, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 2, 2018 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: